Blepharospasm

Evidence-based assessment and management of involuntary eyelid closure. Comprehensive guide covering etiology, pathogenesis, classification, diagnosis, and treatment protocols for optometry practice.

Last updated: March 2026

Fig. 1 — Left: Clinical presentation of benign essential blepharospasm showing forced bilateral lid closure (A), involuntary orbicularis oculi contraction across all three portions (B), brow ptosis / Charcot sign (C), and standard botulinum toxin injection sites (D). Right: Blink reflex neural pathway demonstrating basal ganglia inhibitory dysfunction (E), facial motor nucleus in pons (F), neuromuscular junction — the BTX therapeutic target (G), and sensory triggers via CN V afferents (H). Lower facial involvement (dashed arc) indicates Meige syndrome.

Blepharospasm is a focal cranial dystonia characterised by involuntary, intermittent or sustained contractions of the orbicularis oculi muscle, resulting in forced eyelid closure. It encompasses a spectrum from benign essential blepharospasm (BEB) — the most common primary form — to more complex craniofacial dystonias such as Meige syndrome, which additionally involves the lower face and jaw.

The condition must be distinguished from secondary or reflex blepharospasm, which arises in response to ocular surface irritation (e.g., dry eye, photophobia), and from hemifacial spasm, which is unilateral and caused by facial nerve (CN VII) irritation rather than a primary dystonia. In its most severe form, BEB can cause functional blindness — the patient is unable to open the eyes despite intact visual pathways — profoundly impairing daily function, occupational capacity, and quality of life.

The estimated prevalence of BEB is approximately 36–133 per million, with an annual incidence of 1.4–13.3 per million. It is more common in women (female-to-male ratio approximately 3:1) and typically presents in the fifth to seventh decade of life.

Primary (Idiopathic)

Benign Essential Blepharospasm (BEB): The most common form; no identifiable secondary cause. Thought to reflect primary basal ganglia dysfunction with enhanced excitability of the facial nerve motor nucleus.
Meige Syndrome: BEB combined with oromandibular dystonia; involves involuntary movements of the jaw, tongue, and lower facial muscles.
Genetic factors: A small proportion (<5%) of BEB cases are familial. Mutations in THAP1, TOR1A (DYT1), and GNAL have been implicated in broader dystonia syndromes.

Secondary Causes

Neurological disorders:
- Parkinson's disease and Parkinson-plus syndromes
- Multiple system atrophy (MSA)
- Progressive supranuclear palsy (PSP) — often associated with apraxia of eyelid opening
- Huntington's disease
- Wilson's disease
- Tourette syndrome
- Brainstem lesions (stroke, demyelination)
Drug-induced:
- Dopamine receptor antagonists: antipsychotics (haloperidol, risperidone), metoclopramide, prochlorperazine
- Levodopa (in Parkinson's disease treatment)
- Selective serotonin reuptake inhibitors (SSRIs)
- Calcium channel blockers (flunarizine, cinnarizine)
- Tardive dyskinesia from long-term antipsychotic use
Ocular surface disease (reflex/secondary blepharospasm):
- Dry eye syndrome and meibomian gland dysfunction
- Trichiasis, entropion, distichiasis
- Corneal foreign body, abrasion, or keratitis
- Anterior uveitis and iritis
- Photophobia of any aetiology
- Contact lens-related irritation
Psychogenic/functional: Variable, inconsistent pattern; often context-dependent and partly voluntarily suppressible.
Post-traumatic: Head trauma, periorbital injury, or facial surgery can trigger onset.

Central Neurological Mechanisms

Basal ganglia dysfunction: Abnormal neuroplasticity within the basal ganglia–thalamo–cortical motor circuits is the dominant proposed mechanism. Reduced inhibitory output from the globus pallidus internus (GPi) leads to disinhibition of thalamocortical drive and excessive facial motor cortex activation.
Facial nerve nucleus hyperexcitability: Enhanced excitability of the cranial nerve VII motor nucleus in the pons results in a lower threshold for orbicularis oculi firing, even in the absence of voluntary effort.
Impaired GABAergic inhibition: Reduced GABAergic inhibitory interneuron activity at both brainstem and cortical levels reduces the suppression of the orbicularis reflex arc. Neuroimaging and TMS studies demonstrate decreased cortical inhibition in BEB.
Dopaminergic dysregulation: Dopamine modulates basal ganglia circuitry; striatal dopaminergic dysfunction — consistent with imaging showing reduced dopamine transporter uptake in BEB — contributes to abnormal motor control. This also explains why dopamine-blocking agents can precipitate blepharospasm.
Sensorimotor integration failure: Abnormal integration of afferent sensory signals (from the cornea, conjunctiva, and periocular skin via CN V) with efferent facial motor output leads to disproportionate and misdirected orbicularis responses.
Cortical neuroplasticity changes: Functional MRI studies have demonstrated abnormal activity in the supplementary motor area, premotor cortex, and sensorimotor cortex, suggesting maladaptive plasticity plays a role in perpetuating the dystonic state.

Peripheral and Ocular Surface Contribution

Chronic ocular surface irritation from dry eye, blepharitis, or trichiasis provides persistent afferent input via the trigemino-facial reflex arc. Over time, this heightened peripheral input may sensitise central circuits and precipitate or worsen BEB.
Photosensitivity is prominent: photic stimulation activates the blink reflex pathway and can trigger spasms. The superior colliculus and pretectal area mediate this light-induced reflex, and heightened sensitivity in these pathways amplifies the response.
The geste antagoniste (sensory trick) — in which touching the face, talking, or humming temporarily suppresses spasms — reflects the capacity of competing afferent signals to transiently normalise the aberrant motor output, supporting a sensorimotor rather than purely motor origin.

By Aetiology

Benign Essential Blepharospasm (BEB): Primary focal cranial dystonia; bilateral; no underlying secondary cause. The core diagnosis for most patients.
Meige Syndrome (Brueghel Syndrome): BEB combined with oromandibular dystonia affecting the jaw, tongue, lips, and lower face. Represents segmental craniofacial dystonia.
Hemifacial Spasm (HFS): Unilateral, clonic contractions of CN VII–innervated muscles. Caused by vascular compression of the facial nerve root at the cerebellopontine angle. Distinct from BEB — not a dystonia.
Apraxia of Eyelid Opening (AEO): Inability to voluntarily initiate eyelid opening despite normal or only mildly elevated orbicularis tone. Seen in Parkinson's disease, PSP, and MSA.
Reflex/Secondary Blepharospasm: Protective involuntary lid closure in response to ocular surface disease, photophobia, or pain. Resolves when the underlying cause is treated.
Drug-induced Blepharospasm: Tardive or acute dystonic response to dopaminergic or other medications.

Jankovic Severity Rating Scale (BEB)

The Jankovic Rating Scale (JRS) is the most widely used clinical instrument for grading BEB severity and monitoring treatment response. It comprises a frequency score and severity score, with total scores guiding treatment decisions.

Grade	Spasm Frequency	Functional Impact	Clinical Action
Grade 0	No spasms	None	Monitor; no treatment needed
Grade 1	Increased blink rate; spasms triggered only by external stimuli	Minimal; no functional disability	Treat ocular surface disease; observe
Grade 2	Mild, occasional spontaneous spasms	Slight functional impairment; nuisance-level	Botulinum toxin injections; lifestyle modification
Grade 3	Moderate, frequent spasms	Significant functional impairment; affects driving, reading, work	Regular botulinum toxin; consider adjunctive oral therapy
Grade 4	Severe; near-constant or sustained lid closure	Functional blindness; inability to ambulate safely	Urgent treatment; consider surgical myectomy if botox-refractory

Non-modifiable

Age: Typical onset between 40–70 years; peak incidence in the sixth decade
Female sex: ~3:1 female preponderance; hormonal influences on basal ganglia circuitry postulated
Family history: First-degree relatives of BEB patients have a higher risk; polygenic inheritance likely
Personal or family history of other focal dystonias: Torticollis, writer's cramp, spasmodic dysphonia

Modifiable / Precipitating

Dry eye disease and meibomian gland dysfunction: Chronic ocular surface irritation sensitises the trigemino-facial reflex arc
Photosensitivity: A highly consistent prodromal feature; light sensitivity often precedes overt spasms by months or years
Psychological stress and anxiety: Both a trigger for exacerbation and a comorbidity; anxiety disorders are prevalent in BEB patients
Dopaminergic medication use: Antipsychotics, antiemetics (metoclopramide), and long-term levodopa therapy
Caffeine and fatigue: Both can lower the threshold for spasm initiation
Prior head or periorbital trauma: Physical injury may trigger onset in genetically predisposed individuals
Bright light exposure: Outdoor environments, fluorescent lighting, and screen glare can precipitate or worsen spasms
Concurrently active ocular surface pathology: Blepharitis, trichiasis, anterior uveitis, contact lens wear

Eyelid and Periocular Signs

Bilateral involuntary eyelid closure: The hallmark; usually symmetric; spasms range from forceful squinting to complete lid apposition
Increased blink frequency: Often the earliest detectable sign, preceding overt spasms
Orbicularis hypertrophy: Visible or palpable thickening of the preseptal and pretarsal orbicularis from repeated contraction
Brow ptosis: Downward displacement of the brow from chronic orbicularis overactivity; contributes to a "furrowed" or "angry" appearance
Dermatochalasis: Excess upper eyelid skin, exacerbated by repetitive squeezing movements
Lagophthalmos between spasms: Paradoxical incomplete lid closure during intervals can occur in some cases, contributing to ocular surface desiccation
Geste antagoniste (sensory trick): Temporary reduction in spasm frequency or severity when the patient touches the cheek, talks, sings, or performs an unrelated voluntary facial task; highly suggestive of dystonia
Absence of spasms during sleep: Complete resolution of all spasms in sleep; characteristic of true dystonia and useful in differentiating from psychogenic blepharospasm
Spasm aggravation by: Bright light, reading, driving, emotional stress, fatigue, watching television

Ocular Surface Signs (Secondary Changes)

Conjunctival injection and chemosis
Punctate epithelial erosions (PEE) on fluorescein staining from tear film instability and blink dysfunction
Reduced tear break-up time (TBUT) reflecting concurrent dry eye
Meibomian gland dysfunction signs: telangiectatic lid margins, inspissated meibum, foamy tear meniscus
Signs of concurrent blepharitis: lid margin erythema, collarette deposits

Hemifacial Spasm — Distinguishing Signs

Unilateral: Always starts and remains predominantly ipsilateral
Synchronous contraction of upper and lower face (orbicularis, zygomaticus, mentalis)
Tonus phenomenon: Sustained contraction of lower facial muscles can persist between clonic bursts
Persists during sleep: Unlike BEB, HFS spasms may continue during sleep stages

Excessive, uncontrollable blinking: The most common initial complaint; often mistaken for a nervous habit
Involuntary eyelid closure / functional visual impairment: In moderate to severe cases, inability to open eyes interrupts daily tasks; patients may describe "going blind" temporarily
Photophobia: Prominent and often one of the earliest symptoms; present in up to 90% of BEB patients; bright light (especially fluorescent, LED, and sunlight) triggers or intensifies spasms
Ocular irritation and dryness: Burning, grittiness, foreign body sensation; often reflects concurrent dry eye or the paradoxical desiccation from abnormal blink mechanics
Eye strain and fatigue: Difficulty maintaining open eyes during visual tasks (reading, screen use, driving); near tasks are disproportionately affected
Facial discomfort or pain: Periorbital aching or tension from sustained orbicularis contraction
Tearing: Reflex epiphora from ocular surface irritation
Difficulty driving: A safety-critical concern; many patients are forced to cease driving due to unpredictable lid closure
Social embarrassment: Frequent blinking and facial grimacing cause self-consciousness and social withdrawal
Psychological symptoms: Depression and anxiety are prevalent; may precede or follow the onset of blepharospasm, and are not simply reactive — neurobiological overlap with basal ganglia dysfunction is hypothesised

Note: Symptoms are characteristically worse in bright light, with fatigue, emotional stress, and sustained visual tasks. They typically improve in dim environments, during non-visual activities (walking, speaking), and disappear completely during sleep. This circadian and context-dependent variability is clinically important and should be specifically elicited in history-taking.

Functional and Safety Complications

Functional blindness: Severe, sustained lid closure causing complete visual deprivation despite intact visual pathways; a distinguishing and devastating feature of advanced BEB
Falls and injury: Sudden onset of lid closure while walking, on stairs, or in traffic poses a serious safety risk, particularly in older patients
Driving cessation: A legal and safety concern; most patients with grade 3–4 BEB cannot safely operate a motor vehicle
Occupational disability: Professions requiring sustained visual attention (surgery, precision work, professional driving) may become untenable

Ocular Complications

Exacerbation of dry eye: Abnormal blink dynamics (either reduced interblink interval from spasm or paradoxical lagophthalmos between spasms) impair tear film distribution and accelerate evaporative dry eye
Corneal epitheliopathy: Punctate epithelial erosions and epithelial defects from tear film instability and mechanical trauma
Brow ptosis and secondary visual field loss: Mechanical obstruction of the superior visual field from brow descent
Dermatochalasis with visual obstruction: Redundant upper lid skin further reducing functional visual field

Treatment-related Complications

Botulinum toxin complications:
- Ptosis (most common; from toxin diffusion to levator palpebrae superioris)
- Diplopia (from diffusion to extraocular muscles, particularly inferior oblique)
- Dry eye exacerbation (reduced orbicularis tone impairs lacrimal pump and lid seal)
- Lagophthalmos with exposure keratopathy
- Ectropion or entropion from asymmetric muscle weakening
- Injection site bruising, haematoma
- Secondary antibody formation (immunoresistance) with long-term use — rare with modern dilute preparations
Surgical myectomy complications: Haematoma, wound dehiscence, lymphoedema, lid contour irregularity, recurrence

Psychosocial Complications

Major depressive disorder and anxiety: prevalence substantially higher than age-matched general population
Social isolation and withdrawal from public activities
Reduced health-related quality of life scores (NEI VFQ-25, BEB-related QoL instruments)
Diagnostic delay and patient frustration: average time from symptom onset to diagnosis can exceed 5 years; patients frequently misdiagnosed with anxiety, dry eye, or psychosomatic illness

Associated Neurological Conditions

Parkinson's disease: Blepharospasm and reduced blink rate can both occur. Levodopa treatment may unmask or worsen spasms. Apraxia of eyelid opening is characteristic in advanced Parkinson's disease.
Progressive Supranuclear Palsy (PSP): Apraxia of eyelid opening, blepharospasm, and supranuclear gaze palsy. BEB presenting with vertical gaze restriction warrants MRI brain to exclude PSP.
Multiple System Atrophy (MSA): Blepharospasm and parkinsonian features; poor response to levodopa.
Huntington's disease: Dystonic facial movements including blepharospasm may be part of the motor phenotype.
Wilson's disease: Hepatolenticular degeneration with dystonia, including facial dystonias; presents in younger patients. Kayser-Fleischer rings on slit lamp examination are pathognomonic.
Tourette syndrome: Complex motor and vocal tics may include blepharospasm-like eyelid movements; tics are partly suppressible with voluntarywill — a key differentiating feature.

Systemic Disease — Spread of Dystonia

Approximately 15–20% of BEB patients develop spread of dystonia to adjacent craniocervical regions — oromandibular muscles (Meige syndrome), cervical muscles (torticollis/cervical dystonia), or laryngeal muscles (spasmodic dysphonia).
Spread is more likely when BEB onset is younger and when other focal dystonias are present in the family. Spread beyond the cranial region to the limbs is uncommon in isolated BEB.

Psychiatric Comorbidities

Depression and anxiety disorders affect up to 50–70% of BEB patients. These are not exclusively reactive; neuroimaging suggests a shared pathophysiological substrate involving cortico-limbic-basal ganglia networks.
Obsessive-compulsive disorder (OCD) has been reported at higher-than-expected frequency in focal dystonia populations.
Psychosocial screening should be routine in BEB management — untreated comorbid depression significantly impairs treatment response and quality-of-life outcomes.

Systemic Workup Indications

Refer to neurology for systemic evaluation when:

Unilateral presentation (consider hemifacial spasm — MRI posterior fossa required)
Onset below age 40 (consider Wilson's disease — serum ceruloplasmin, 24-hour urine copper, slit lamp for KF rings)
Associated parkinsonism, gaze palsy, or other neurological signs (consider Parkinson's disease, PSP, MSA)
Drug-history positive for known causative agents — consider discontinuation under medical supervision
Rapid or atypical onset with concurrent systemic symptoms
Spread of dystonia beyond periorbital region to jaw, neck, or larynx

Clinical History

Duration, onset pattern (insidious vs. acute), and rate of progression
Laterality: bilateral (BEB) vs. unilateral (hemifacial spasm)
Aggravating factors: bright light, fatigue, stress, reading, driving
Relieving factors: darkness, closing one eye, geste antagoniste manoeuvres
Presence during sleep vs. complete resolution — a key diagnostic clue
Associated neurological symptoms: tremor, bradykinesia, dysphagia, gait disturbance
Psychiatric history: depression, anxiety, OCD
Drug history: antipsychotics, antiemetics, levodopa, SSRIs, calcium channel blockers
Family history of dystonias, Parkinson's disease, or tremors
Occupational and functional impact: driving, reading, employment

Clinical Examination

1. Observation and Functional Assessment:

Observe patient during casual conversation and at rest — note blink frequency, spontaneous spasms, facial grimacing
Assess response to bright light (photoactivation test): directed light source or ophthalmoscope beam can provoke spasms
Test for geste antagoniste: ask patient to touch cheek or hum; observe for spasm attenuation
Assess voluntary eyelid opening: differentiate BEB (can open between spasms) from AEO (persistent difficulty initiating opening)
Assess symmetry — unilateral vs. bilateral involvement

2. Periocular and Lid Assessment:

Orbicularis tone and visible hypertrophy
Brow position and degree of brow ptosis
Presence of dermatochalasis
Facial motor examination: assess lower face for Meige syndrome features (jaw clenching, tongue protrusion)
Palpate for supraorbital nerve tenderness (suggests trigeminal sensitisation)

3. Slit Lamp Biomicroscopy:

Cornea: Fluorescein staining for punctate epithelial erosions; assess corneal surface regularity
Tear film: TBUT assessment; tear meniscus height; assess for aqueous deficiency and evaporative dry eye
Lid margin: Signs of blepharitis, meibomian gland disease, trichiasis — identify and treat any reflex triggers
Conjunctiva: Injection, papillary or follicular reaction, goblet cell loss
Anterior chamber and iris: Rule out anterior uveitis as a cause of reflex blepharospasm
Kayser-Fleischer rings: Examine limbal cornea in younger patients with dystonia — KF rings indicate Wilson's disease

4. Supplementary Tests and Imaging:

Meibography (infrared):

Quantify meibomian gland dropout and distortion contributing to evaporative dry eye and reflex component
Graded using Meiboscore (0–3 per lid) or Pult Meibomian Gland Coverage Index

Fluorescein Staining (slit lamp, cobalt-blue filter):

Interpalpebral and inferior PEE pattern suggests dry eye / evaporative disease exacerbating spasm reflex arc
Oxford Grade or NEI grading for standardised documentation
Resolving corneal staining after treatment of surface disease confirms a reflex aetiology

MRI Brain (ordered by ophthalmologist or neurologist):

Mandatory for unilateral presentation to identify posterior fossa vascular loop causing hemifacial spasm (FIESTA/CISS sequences)
Indicated if parkinsonism, vertical gaze palsy, or other neurological signs are present (PSP, MSA, Wilson's)
Not routinely required for typical bilateral BEB presentation

Electromyography (EMG) — specialist use:

Confirms orbicularis over-activity and distinguishes from myokymia or other neuromuscular conditions
Blink reflex studies demonstrate hyperexcitability of the R2 component of the blink reflex in BEB
Not required for routine clinical diagnosis

Jankovic Rating Scale (JRS) — clinical scoring tool:

Frequency score (0–4) + Severity score (0–4) = Total (0–8); apply at baseline and each follow-up
Standardises monitoring of disease progression and treatment response across visits

Singapore Optometry Scope Note: Optometrists may identify and grade blepharospasm, manage contributing ocular surface disease (dry eye, MGD, blepharitis), and prescribe FL-41 tinted or photochromic lenses to reduce photosensitivity. Anterior segment assessment (slit lamp, meibography, fluorescein staining) is within scope. Definitive diagnosis and botulinum toxin treatment require referral to an ophthalmologist (oculoplastics) or neurologist. As optometrists in Singapore do not perform dilated fundus examination, posterior segment assessment — warranted when an underlying neurological cause (e.g. PSP, Parkinson's disease, Wilson's disease) is suspected — must be referred to an ophthalmologist.

1. Treat Underlying Triggers (First Step in All Cases)

Dry eye disease: Aggressive lubrication with preservative-free artificial tears (aqueous and lipid-based), warm compresses, lid hygiene, omega-3 supplementation, lid hygiene, and meibomian gland expression. Reducing ocular surface inflammation decreases the afferent trigeminal input sustaining spasms.
Blepharitis and MGD: Twice-daily warm compresses, lid scrubs, azithromycin 1% ophthalmic drops or erythromycin ointment; consider oral doxycycline 50 mg OD for refractory MGD (requires medical prescription in Singapore)
Review and cease causative medications: Drug-induced blepharospasm from antipsychotics, antiemetics, or SSRIs should be addressed with the prescribing physician

2. Optical and Protective Measures

FL-41 tinted lenses: A rose-tinted filter (peak transmittance around 590 nm, blocking 511 nm shortwavelength band) has been shown in randomised controlled trials to reduce blink rate and spasm severity by attenuating the photic-trigger pathway. Recommended for all photosensitive BEB patients.
Photochromic (variable-tint) and polarised lenses: Reduce photic triggers in outdoor environments; wraparound frames provide additional lateral light shielding
UV-blocking contact lenses: May offer adjunctive photosensitivity relief in suitable candidates
Ptosis crutches (lid crutches): Spectacle-mounted wire supports to mechanically hold the upper lid open; useful in severe AEO or botox-related ptosis as a temporary measure

3. Botulinum Toxin Type A Injections (First-line Definitive Treatment)

Botulinum toxin type A (BoNT-A) is the first-line and most effective treatment for BEB, supported by Level I evidence and endorsed by movement disorder and oculoplastic guidelines worldwide. It acts by blocking acetylcholine release at the neuromuscular junction, producing temporary, reversible orbicularis paralysis.

Injection sites: Preseptal and pretarsal orbicularis oculi (upper and lower lids); lateral canthal injection for complete treatment
Dose per session: Typically 25–50 units onabotulinumtoxinA (Botox) or equivalent per eye, distributed across 4–6 injection sites
Onset: 2–7 days post-injection
Duration: 3–4 months; repeat injections required 3–4 times per year
Success rate: Symptom reduction in 70–90% of patients; complete relief in a subset
Long-term efficacy: Maintained over years with repeated injections; dose may require adjustment over time
Common adverse effects: Ptosis (most common), dry eye, diplopia, bruising at injection site; usually transient (2–4 weeks)

4. Oral Pharmacotherapy (Adjunctive)

Oral agents are second-line options when botulinum toxin provides incomplete relief or is not tolerated. Efficacy is generally modest.

Clonazepam (benzodiazepine): GABAergic enhancement; may reduce spasm frequency; limited by sedation and dependence
Trihexyphenidyl (anticholinergic): Modest efficacy in some patients; limited by cognitive side effects in older adults
Baclofen (GABA-B agonist): Adjunctive benefit, particularly in Meige syndrome
Tetrabenazine (monoamine depleter): Occasionally used in refractory cases; requires close monitoring

5. Surgical Management (Botox-refractory Cases)

Limited myectomy: Surgical stripping of the preseptal and pretarsal orbicularis oculi, with or without brow fat pad removal; produces sustained improvement in ~80% of selected patients; more durable than repeated botox alone
Extended myectomy: Additional resection of the procerus and corrugator supercilii muscles; for severe cases with brow ptosis contribution
Facial nerve avulsion or neurectomy: Historical procedure; largely abandoned due to high recurrence and significant morbidity
Deep Brain Stimulation (DBS) of the globus pallidus internus: Reserved for rare, severe, medically refractory BEB or Meige syndrome; limited case series data support its use in carefully selected patients
Blepharoplasty and brow lift: For symptomatic dermatochalasis and mechanical brow ptosis after spasm control is achieved

Treatment Selection Guide

Severity (JRS)	First-line	Adjunctive	Referral
Grade 1 (Mild)	Ocular surface treatment; FL-41 tint; photochromic lenses	Lubricating drops; lifestyle modification; stress management	Ophthalmology if no improvement
Grade 2–3 (Moderate)	Botulinum toxin A injections	FL-41 tint; dry eye treatment; oral agents if partial response	Ophthalmology (oculoplastics) or neurology
Grade 4 (Severe)	Botulinum toxin A; consider surgical myectomy if refractory	Oral pharmacotherapy; DBS if all else fails	Urgent ophthalmology and neurology co-management

Natural History

BEB is a chronic, often progressive condition in the majority of patients, particularly in the first 3–5 years after onset
Spontaneous remission occurs in approximately 10–20% of patients; more common in younger patients and those with a shorter duration of symptoms. Remissions may be incomplete or temporary.
Without treatment, the condition tends to worsen: patients progress from increased blink rate through intermittent to persistent spasms and eventual functional blindness
Spread of dystonia to adjacent craniocervical regions occurs in 15–20% of patients over the course of the disease

Prognosis with Treatment

Botulinum toxin: Provides excellent symptomatic control in 70–90% of patients; most maintain functional vision with regular injections. Efficacy is generally sustained over years of treatment.
Immunoresistance to BoNT-A develops in a small percentage of patients (<5%) after long-term treatment; switching to BoNT-B (Myobloc/Neurobloc) may be effective in these cases
Surgical myectomy: Produces sustained improvement in ~80% of selected cases with significant morbidity in a minority; provides longer inter-treatment intervals in some patients
Quality of life is significantly impaired in untreated BEB but improves substantially — approaching near-normal levels — with successful botulinum toxin therapy
Hemifacial spasm following microvascular decompression surgery has a high cure rate (>85% long-term), with low recurrence
Secondary/reflex blepharospasm has an excellent prognosis when the causative ocular surface disease is effectively treated; spasms typically resolve completely

Condition	Key Differentiating Features	Laterality	During Sleep
Benign Essential Blepharospasm (BEB)	Bilateral involuntary closure; photophobic; geste antagoniste positive; dystonic pattern	Bilateral	Absent
Hemifacial Spasm	Unilateral; starts periorbital then spreads to lower face; CN VII irritation (vascular loop); tonus phenomenon	Unilateral	May persist
Dry Eye / Ocular Surface Disease	Reflex blepharospasm; resolves with surface disease treatment; no spontaneous spasms at rest in dim light	Bilateral or unilateral	Absent
Eyelid Myokymia	Fine, focal, undulating twitching (fasciculation) of one lid segment; benign; associated with fatigue, caffeine, stress; self-limiting	Unilateral (one lid)	Absent
Apraxia of Eyelid Opening (AEO)	Inability to voluntarily open lids; normal or mildly increased orbicularis tone; associated with Parkinson's/PSP; no forceful involuntary closure	Bilateral	Absent
Meige Syndrome	BEB + oromandibular dystonia (jaw clenching, tongue protrusion, grimacing); broader craniofacial distribution	Bilateral	Absent
Tardive Dyskinesia	History of antipsychotic use; repetitive oro-facial movements including lip-smacking, tongue protrusion, jaw movements; may co-exist with blepharospasm	Bilateral	Variable
Tic Disorder / Tourette Syndrome	Voluntary suppression possible (temporarily); complex motor and vocal tics; childhood or adolescent onset; worsens under stress; semi-purposeful quality	Variable	Absent or reduced
Functional (Psychogenic) Blepharospasm	Inconsistent pattern; responds disproportionately to suggestion; absence of geste antagoniste; variable and context-dependent; psychiatric comorbidity prominent	Variable	Absent
Ptosis (Mechanical or Neurogenic)	Lid droops due to levator weakness or mechanical load — no spasm; differentiated by lack of active orbicularis contraction	Unilateral or bilateral	Absent

Key Diagnostic Principle: The combination of bilaterality, photosensitivity, geste antagoniste, complete resolution during sleep, and absence of lower facial involvement reliably identifies benign essential blepharospasm. Any unilateral presentation mandates imaging to exclude hemifacial spasm and its neurovascular cause. Any presentation with parkinsonism, gaze palsy, or dystonia onset below age 40 warrants prompt neurological referral and neuroimaging.

Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol. 1984;16(4):371–376.
Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863–873.
Defazio G, Hallett M, Jinnah HA, Berardelli A. Development and validation of a clinical guideline for diagnosing blepharospasm. Neurology. 2013;81(3):236–240.
Hallett M, Albanese A, Dressler D, et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders. Toxicon. 2013;67:94–114.
Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A therapy for blepharospasm. Cochrane Database Syst Rev. 2005;(1):CD004900.
Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol. 2007;52(1):13–31.
Kraft SP, Lang AE. Cranial dystonia, blepharospasm and hemifacial spasm: clinical features and treatment, including the use of botulinum toxin. CMAJ. 1988;139(9):837–844.
Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthalmic Plast Reconstr Surg. 1998;14(5):305–317.
Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. 1988;51(6):767–772.
Weiss EM, Hershey T, Karimi M, et al. Relative risk of spread of symptoms among the focal onset dystonias. Mov Disord. 2006;21(8):1175–1181.
Wang A, Jankovic J. Hemifacial spasm: clinical findings and treatment. Muscle Nerve. 1998;21(12):1740–1747.
Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review). Neurology. 2008;70(19):1707–1714.
Bradley EA, Bartley GB, Chapman KL, Waller RR. Surgical correction of blepharospasm. Am J Ophthalmol. 1991;112(5):594–598.
Blackburn MK, Lamb RD, Digre KB, et al. FL-41 tint improves blink frequency, light sensitivity, and functional limitations in patients with benign essential blepharospasm. Ophthalmology. 2009;116(5):997–1001.
McCann JD, Bhatt H. Management of blepharospasm: a review. Curr Opin Ophthalmol. 2021;32(5):475–481.

Clinical Illustration

Overview

Etiology